Skip to main content
Paul Haluska Jr., MD, Oncology, Rochester, MN

PaulHaluskaJr.MD

Oncology Rochester, MN

Breast Cancer, Gynecologic Cancer

Associate Professor, Oncology, Mayo Medical School

Dr. Haluska is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Haluska's full profile

Already have an account?

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2003 - 2006
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2000 - 2003
  • Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical SchoolClass of 2000
  • Graduate School of Biomedical Sciences/UMDNJ-Robert Wood Johnson Medical School, Rutgers The State University of New Jersey
    Graduate School of Biomedical Sciences/UMDNJ-Robert Wood Johnson Medical School, Rutgers The State University of New JerseyPh.D., Pharmacology, 1995 - 1998
  • College of Arts and Sciences, Indiana University, Bloomington
    College of Arts and Sciences, Indiana University, BloomingtonB.S., Biochemistry, 1988 - 1992

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2001 - 2015

Awards, Honors, & Recognition

  • Mayo Clinic Ovarian SPORE Career Development Award Mayo Clinic, 2009
  • Mayo Clinic Breast SPORE Career Development Award Mayo Clinic, 2007
  • Young Investigator Award American Society of Clinical Oncology, 2006
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 1b Study of Safety, Tolerability and Efficacy of R1507, a Monoclonal Antibody to Igf-1r in Combination with Multiple Standard Oncology Regimens in Patients with ...  
    Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJE, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R, Cancer Chemother Pharmacol, 3/1/2014
  • Low Expression of Insulin-Like Growth Factor Binding Proteins Predicts Poor Outcomes in Ovarian Cancer Patients  
    Glaser G, Haluska P, Harrington SC, Farzan T, Winterhoff BJ, Goodman KM, Kalli KR, Konecny GE, Gynecologic Oncology, 1/1/2013
  • Multifocal Neuropathy as the Presenting Symptom of Purkinje Cell Cytoplasmic Autoantibody-1  
    Bradshaw MJ, Haluska P, Mckeon A, Klein CJ, Muscle Nerve, 1/1/2013
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Novel Strategies to Target the C5 Subclass of High-grade Serous Ovarian Cancer Using Patient-derived Xenografts
    Haluska P, 15th Biennial Meeting of the International Gynecologic Cancer Society, Melbourne, Australia, 11/1/2014
  • Randomized Phase II Trial of Capecitabine and Lapatinib +/- IMC-A12 in Patients with HER2+ Breast Cancer Previously Treated Iwth Trastuzumab and an Anthracycline And/o...
    Haluska P, ASCO Annual Meeting, Chicago, Illinois, 6/1/2014
  • Overexpression of IGF-2 in Primary Patient Ovarian Cancer Tumorgrafts Increases Bowel and Thoracic Metastasis
    Haluska P, AACR Annual Meeting, San Diego, California, 4/1/2014
  • Join now to see all

Lectures

  • Homologous Recombination Deficiency (HRD) Score and Niraparib Efficacy in High Grade Ovarian Cancer 
    Barcelona, Spain - 11/1/2014
  • The Mayo Ovarian Avatar Program: Of Mice And (Wo)men 
    Birmingham, Alabama - 10/1/2014
  • Lessons Learned from Targeting the IGF-1R and Implications for Cancer Prevention 
    New Orleans, Louisiana - 10/1/2014
  • Join now to see all

Other

  • Ovarian Cancer 
    Mayo Clinic Radio
    9/1/2013
  • Amgen Review Web-based Seminar 
    Haluska P., San Antonio Breast Cancer Symposium
    1/1/2010